CRMD
CorMedix Inc.
$8.40
-0.27
(-3.11%)
Mkt Cap
659.00M
Volume
777,931
52W Range
6.13-14.96
Sector
Healthcare
Beta
1.48
EPS (TTM)
2.38
P/E Ratio
3.53
Revenue (TTM)
400.05M
Rev Growth (5Y)
+319.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$55.70
Undervalued
strong signal
84.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 311.71M | 43.47M | 0 | 65,408 | 190,936 | 239,231 | 283,266 | 429,797 | 329,327 | 224,105 | 210,130 | 189,274 |
| Net Income | 163.06M | (17.93M) | (46.34M) | (29.70M) | (28.21M) | (22.03M) | (16.43M) | (26.83M) | (33.01M) | (24.64M) | (18.19M) | (20.45M) |
| EPS | 2.25 | -0.30 | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 |
| Free Cash Flow | 172.79M | (50.73M) | (38.74M) | (24.58M) | (22.58M) | (22.08M) | (15.09M) | (23.75M) | (28.74M) | (22.32M) | (12.54M) | (6.35M) |
| FCF / Share | 2.40 | -0.86 | -0.76 | -0.61 | -0.60 | -0.77 | -0.62 | -1.33 | -2.61 | -2.94 | -2.00 | -1.48 |
| Operating CF | 175.05M | (50.61M) | (38.41M) | (24.36M) | (21.16M) | (21.97M) | (15.05M) | (23.70M) | (28.59M) | (22.27M) | (12.53M) | (6.32M) |
| Total Assets | 826.14M | 118.85M | 82.06M | 62.04M | 68.95M | 49.31M | 29.48M | 18.83M | 13.45M | 21.91M | 37.10M | 5.10M |
| Total Debt | 148.91M | 517,013 | 667,632 | 802,433 | 923,801 | 1.03M | 4,689 | 6.13M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 145.82M | 40.65M | 43.64M | 43.37M | 53.32M | 41.91M | 16.53M | 17.62M | 10.38M | 8.06M | 11.82M | 4.34M |
| Book Value | 405.31M | 84.66M | 70.14M | 55.06M | 62.80M | 44.22M | (195.42M) | (178.99M) | (152.17M) | 17.81M | 34.01M | 3.63M |
| Return on Equity | 0.40 | -0.21 | -0.66 | -0.54 | -0.45 | -0.50 | N/A | N/A | N/A | -1.38 | -0.53 | -5.63 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.43M | 128.62M | 104.28M | 39.74M | 39.08M | 31.21M | 11.46M | 806,119 | 0 | 0 | 0 | 0 |
| Net Income | 38.60M | 14.02M | 108.56M | 19.83M | 20.64M | 13.46M | (2.78M) | (14.15M) | (14.47M) | (14.75M) | (9.74M) | (11.27M) |
| EPS | 0.49 | 0.18 | 1.42 | 0.29 | 0.32 | 0.22 | -0.05 | -0.25 | -0.25 | -0.26 | -0.17 | -0.25 |
| Free Cash Flow | 41.65M | 94.42M | 30.35M | 29.97M | 19.73M | (5.62M) | (13.66M) | (14.07M) | (17.37M) | (11.04M) | (8.71M) | (8.58M) |
| FCF / Share | 0.52 | 1.20 | 0.40 | 0.44 | 0.30 | -0.09 | -0.23 | -0.24 | -0.30 | -0.19 | -0.15 | -0.19 |
| Operating CF | 42.38M | 94.46M | 30.86M | 29.99M | 19.74M | (5.61M) | (13.65M) | (14.04M) | (17.31M) | (10.75M) | (8.70M) | (8.57M) |
| Total Assets | 815.64M | 826.14M | 750.86M | 252.60M | 149.58M | 118.85M | 77.59M | 57.73M | 68.02M | 82.06M | 91.43M | 57.03M |
| Total Debt | 144.88M | 148.91M | 148.92M | 435,245 | 476,587 | 517,013 | 556,416 | 594,323 | 631,389 | 667,632 | 702,947 | 736,855 |
| Cash & Equiv | 178.09M | 145.82M | 48.49M | 159.31M | 66.29M | 40.65M | 35.29M | 28.54M | 35.18M | 43.64M | 53.31M | 19.79M |
| Book Value | 437.05M | 405.31M | 374.13M | 220.63M | 114.89M | 84.66M | 58.71M | 46.18M | 58.01M | 70.14M | 83.20M | 49.05M |
| Return on Equity | 0.09 | 0.03 | 0.29 | 0.09 | 0.18 | 0.16 | -0.05 | -0.31 | -0.25 | -0.21 | -0.12 | -0.23 |
CRMD News
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript